Trial Search Results
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Stanford is currently not accepting patients for this trial.
- Drug: topotecan
- Drug: CARBOPLATIN
- Subject must have baseline laboratory values as follows:
- Hemoglobin 9.0 g/dL
- Neutrophils 1,500/mm3
- Platelets 100,000/mm3
- Creatinine 1.5 mg/dL ( 133 mol/l) or creatinine clearance 60 mL/min
- Serum bilirubin < 2.0 mg/dL (< 35 umol/L)
- SGOT/AST, SGPT/ALT and alkaline phosphatase < 2 times ULN if liver metastases are
absent by abdominal CT or MRI or < 5 times ULN if liver metastases are present
- Subject is allowed to have received, but is not required to have received, one
additional prior non-cytotoxic regimen for management of recurrent or persistent
disease according to the following definition: Non-cytotoxic (biologic or cytostatic)
agents include (but are not limited to) monoclonal antibodies, cytokines, and
small-molecule inhibitors of signal transduction
- Subject is female 18 years of age with an ECOG Performance Status of 0, 1 or 2
- Subject has recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
which was histologically confirmed at the time of the primary diagnosis
- Subject has received one prior platinum-based chemotherapeutic regimen (containing
either carboplatin or cisplatin) for the treatment of primary disease. Consolidation
chemotherapy is not permitted
- Subject's disease is considered potentially platinum-sensitive (i.e., have had a
platinum-free interval following complete response to carboplatin or cisplatin of
greater than 6 months)
- Subject must have at least one measurable lesion as determined by diagnostic studies
including CT or MRI or physical exam. Measurable disease must be accurately measured
in at least one dimension (longest dimension to be recorded). Each lesion must be 20
mm in their longest dimension when measured by conventional techniques, including
palpation, plain X-ray, CT and MRI, or 10 mm when measured by spiral CT. Palpable
tumor masses that cannot be evaluated radiologically must have 2 diameters 20 mm. An
attempt to document lesion size by ultrasound should be undertaken for palpable
lesions not visualized on CT (or MRI).
- The same diagnostic imaging method used to evaluate disease must be used throughout
the study to evaluate lesions consistently
- Stable blood, liver and renal functions.
- Subjects of child-bearing potential must be practicing adequate contraception (e.g.
oral contraceptives, diaphragm plus spermicide, or IUD) for at least 3 months prior to
study start. The same contraceptive method should be used throughout the study and
continue for at least 4 weeks after the end of the study
- Pregnant or lactating.
- Subject has received more than 1 prior chemotherapy regimen or a history of
consolidation cytotoxic chemotherapy
- Subject has concomitant or history of previous malignancies, with the exception of
adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
or other cancer from which the subject has been disease-free for 5 years
- Subject has brain metastases as documented by CT or MRI. Note: Asymptomatic subjects
do not require CT or MRI to rule out brain metastases
- Received previous treatment with HYCAMTIN.
- Subject has received an investigational agent within 30 days or 5 half-lives
(whichever is longer) prior to study entry
- Received prior radiation therapy for ovarian cancer
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study